TTC Oncology
Company profile on P2PMarketData. TTC Oncology is a biotechnology company based in Minneapolis, United States, founded in 2015. It has raised $141.8K through crowdfunding on Wefunder.
TTC Oncology holds a worldwide exclusive license from the University of Illinois Chicago covering therapeutic modulation of the estrogen receptor in ER+ breast cancer. It is developing TTC-352, a selective ER partial agonist with a novel mechanism of action for hormone resistant, ER+/HER2- breast cancer, and has discovered a biomarker identifying breast cancer likely to respond to the therapy. TTC-352 has completed a Phase 1 clinical trial.
Frequently asked questions about TTC Oncology
How much funding has TTC Oncology raised?
TTC Oncology has raised $141.8K through crowdfunding across 1 round tracked by P2PMarketData, from 69 investors.
What is TTC Oncology's valuation?
TTC Oncology had an indicative valuation of $25M in its 2021 funding round.
Is TTC Oncology profitable?
No. TTC Oncology reported a net loss of $99.6K for fiscal year 2020.
How many employees does TTC Oncology have?
TTC Oncology reported 1 employee for fiscal year 2020.
When was TTC Oncology founded?
TTC Oncology was founded in August 2015.
Where is TTC Oncology based?
TTC Oncology is headquartered in Minneapolis, Minnesota, United States, and is incorporated in Delaware, United States.
What industry is TTC Oncology in?
TTC Oncology operates in the Biotechnology industry within the Healthcare sector.